MTAP-deleted Solid Tumors study: BAY
Official title A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
ClinicalTrials.gov ID: NCT06914128
What this study is testing
What is BAY 3713372?
an investigational oral medicine being studied for MTAP‑deleted solid tumors is designed to block the protein arginine N‑methyltransferase 5 (PRMT5) which may kill MTAP‑deleted cancer cells while sparing normal cells
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn how safe BAY 3713372 is, how the body handles it, and whether it shows any early anti‑cancer activity in people with MTAP‑deleted solid tumors.
- Who it's for
- Adults who have a solid tumor that is missing the MTAP gene.
- What's involved
- Participants will receive BAY 3713372 (alone or with other treatments) and undergo regular blood and urine tests, heart checks (ECG), imaging scans (CT/MRI), and occasional tumor biopsies.
- Time commitment
- The trial includes several visits before treatment, multiple visits during treatment, a check 30 days after the last dose, then visits every 9 weeks until the cancer progresses, plus follow‑up contacts every 3 months for up to 2 years.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time...
- At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You likely can't join if
- Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the...
- A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval \>450 ms).
- History of congestive heart failure Class \>II according to the New York Heart Association Functional Classification.
- Myocardial infarction less than 6 months before the start of study intervention.
- Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the...
- Unstable angina within 4 weeks before start of study intervention.
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Denver, Colorado, United States
- Orlando, Florida, United States
- Boston, Massachusetts, United States
- Grand Rapids, Michigan, United States
- New York, New York, United States
- Nashville, Tennessee, United States
- Irving, Texas, United States
- San Antonio, Texas, United States
- Camperdown, New South Wales, Australia
- Concord, New South Wales, Australia
- Waratah, New South Wales, Australia
- Antwerp, Antwerp, Belgium
- Ghent, East Flanders, Belgium
- Leuven, Flemish Brabant, Belgium
- Liège, Liège, Belgium
- Beijing, Beijing Municipality, China
- Wuhan, Hubei, China
- Olomouc, Olomouc Region, Czechia
- Brno, South Moravian, Czechia
+ 21 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Denver, Colorado, United States; Orlando, Florida, United States; Boston, Massachusetts, United States; Grand Rapids, Michigan, United States; New York, New York, United States and 35 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.